急性肾损伤分期下降可预测1型肝肾综合征患者生存
本研究基于特利加压素治疗1型肝肾综合征的随机双盲安慰剂对照研究,纳入184例患者,按入组时AKI分期分层。多因素分析显示无酒精性肝炎、基线血肌酐和男性是AKI改善的预测因素。AKI分期下降与90天总生存显著相关(P=0.0022),且独立于HRS逆转,初始AKI 1期患者临床获益最大。
要点
- AKI分期下降独立于HRS逆转,与90天生存改善显著相关(P=0.0022)。
- 初始AKI 1期患者若AKI改善,临床获益最大。
- HRS-1治疗目标应比绝对HRS逆转更宽松。
核心结论
- AKI分期下降独立于HRS逆转,足以改善HRS-1患者总生存。
- HRS-1治疗目标应比绝对HRS逆转更宽松。
研究设计与样本
- 随机、安慰剂对照、双盲研究(特利加压素 vs 安慰剂,均联合白蛋白,治疗≤14天)。
- 共纳入184例HRS-1患者(特利加压素91例,安慰剂93例),按入组时AKI分期1-3期分层。
主要发现
- AKI改善的预测因素为无酒精性肝炎、基线血清肌酐和男性。
- 总体生存率在各AKI分期间无显著差异(范围53-65%)。
- 无AKI恶化患者中,AKI改善者90天生存 consistently 更好,独立于HRS逆转,初始1期患者获益最大。
- AKI下降与90天总生存显著相关(P=0.0022)。
临床怎么用
- 监测HRS-1患者AKI分期变化,即使未达HRS逆转,AKI改善也提示生存获益。
- 治疗目标可设定为AKI分期下降而非仅追求HRS完全逆转。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated. The impact of reduction in AKI stage on overall survival in cirrhosis, independent of HRS reversal, is unclear. METHODS: The Randomized, placEbo-controlled, double-blind study to confirm the reVERSal of HRS-1 with terlipressin study assessed terlipressin versus placebo, both with albumin, as treatment for HRS-1 for ≤14 days. Renal dysfunction severity was categorized by AKI stage at enrollment. Baseline patient characteristics were evaluated as predictors of AKI improvement using a multivariate model; the association between AKI stage reduction and 90-day survival was assessed using linear regression. RESULTS: A total of 184 patients (terlipressin: n = 91; placebo: n = 93) with similar numbers in AKI Stages 1-3 (terlipressin/placebo, Stage 1: n = 25/26; Stage 2: n = 35/33; Stage 3: n = 31/34) were included. Predictors of AKI improvement were absence of alcoholic hepatitis, baseline serum creatinine and male gender. Overall survival was not significantly different across AKI stages (range 53-65%). In patients with no AKI worsening, 90-day survival was consistently better when AKI improved independent of HRS reversal, regardless of the initial AKI stage, with patients with Stage 1 at initial diagnosis achieving the greatest clinical benefit. A significant association was observed between AKI reduction and overall 90-day survival (P = 0.0022). CONCLUSIONS: A reduction in AKI stage, independent of HRS reversal, was sufficient to improve overall survival in patients with HRS-1. The goal for HRS-1 treatment should be less stringent than absolute HRS reversal.
引用
- Wong F, Boyer TD, Sanyal AJ, et al. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. Nephrol Dial Transplant. 2020. PMID: 30887050. doi:10.1093/ndt/gfz048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。